COMPANY PROFILE

Hoba Therapeutics

Developer of neuropathic pain and CNS therapies. The company develops biopharmaceuticals for chronic pain and hearing loss

Copenhagen, DenmarkFounded 2016Biotech & Life Sciences

Valuation $100–250M Last recorded · 2023

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Hoba Therapeutics

Developer of medical therapeutics designed to assist neuropathic pain and CNS disorders treatments. The company specializes to develop novel biopharmaceuticals for the relief, prevention, and treatment of chronic pain and hearing loss and advancing a novel therapeutic protein targeting the cells, enabling medical practitioners with innovative effective, safe, and disease-modifying treatments for patients living with neuropathic pain. Keywords: Pharmaceuticals and Biotechnology, Bio Treatment, Nervous System, Neuropathic Pain Drugs, Pharmaceutical, Postherpetic Neuralgia, Systemic Illness, Therapeutic Protein.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Copenhagen, Denmark
Employees: 5
Open positions: None listed
Dealroom signal: 58.4/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Innovation Management, Developer Tools, Biotechnology, EIC, Biotech and Pharma, EIC Fund, Hard Tech, Horizon Europe, proteomics, DT and LS
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Dec 2023	$25M	$101M	Export and Investment Fund of Denmark · Novo Holdings · EIC Fund · Eir Ventures	↗
EARLY VC✓Equity / VC	Oct 2021	$0	—	EIC Fund	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Profit	Margin
2026		—
2025		—
2024		—
2023		—
2022		—
2021		—
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Hoba Therapeutics website traffic

Latest recorded traffic for Hoba Therapeutics is 270 monthly website visits, down 35.7% over the last three months. Hoba Therapeutics's team declined 54.5% over the past year.

Latest monthly visits270 3-month web change-35.7% 1-year team growth-54.5%

Monthly website visitsDec 2018–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
HPHerantis PharmaInnovative biotech company developing disease modifying therapies for Parkinson’s disease	Helsinki, Finland	Operational	24	$18M	$28M
PEPeptomycFoundational anti-MYC mini-proteins for cancer treatment	Barcelona, Spain	Operational
SESentanteDeveloping a radiation-reducing manipulator and a minimally invasive coronary robotic system for endovascular procedures	Kaunas, Lithuania	Operational
PTPROSION TherapeuticsPROSION Therapeutics is a drug development company with a proprietary platform that addresses highly unmet medical needs by unlocking undruggables	Cologne, Germany	Operational
AAAlginor ASAAlginor's green innovation, AORTA, increases the utilisation ratio of seaweeds from approximately 15 to 100% without using formaldehyde and other harmful chemicals	Haugesund, Norway	Operational
OSOsivaxA company developing "universal" vaccines able to prevent highly-mutating respiratory viral infections	Lyon, France	Operational
IBInterAx BiotechDelivering High-Quality Drug Candidates for GPCR Targets	Villigen, Switzerland	Operational
IPIlya PharmaIlya Pharma develops immune-cell therapies. The company's biological medicine uses lactic acid bacteria as vectors to deliver biological drugs on-site to skin wounds or the GI tract	Uppsala kommun, Sweden	Operational